West Pharmaceutical Services Management
Management Kriterienprüfungen 4/4
West Pharmaceutical Services CEO ist Eric Green , ernannt in Apr 2015, hat eine Amtszeit von 11.17 Jahren. Die jährliche Gesamtvergütung beträgt $7.19M , bestehend aus 16.4% Gehalt und 83.6% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.25% der Aktien des Unternehmens, im Wert von $57.39M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.4 Jahre bzw. 10.4 Jahre.
Wichtige Informationen
Eric Green
Geschäftsführender
US$7.2m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 16.37% |
| Amtszeit als Geschäftsführer | 11.2yrs |
| Eigentum des Geschäftsführers | 0.3% |
| Durchschnittliche Amtszeit des Managements | 2.4yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 10.4yrs |
Jüngste Management Updates
Recent updates
Narrativ-Update • Jun 06
WST: Injectable Platforms And High Value Mix Will Support Future Earnings Power
Analysts have nudged their fair value estimate for West Pharmaceutical Services higher to about $352 per share, citing refreshed price targets around $325 to $375 and continued confidence in injectable driven growth and execution. Analyst Commentary Recent Street research has focused on how West Pharmaceutical Services is executing on growth in injectables and high value product categories, and what that could mean for valuation as price targets shift higher.Seeking Alpha • Apr 30
West Pharmaceutical: Multiple Growth Drivers Are A Tailwind
Summary West Pharmaceutical Services maintains dominant market share in injectable drug delivery, underpinned by a wide moat and robust regulatory positioning. WST reported strong Q1 2026 results, with revenue up 21% and adjusted EPS up 46.9%, prompting a guidance raise and share price rebound. Key growth drivers include biologics market expansion, GLP-1 drug demand, and Annex 1 regulatory upgrades, supporting recurring revenue and margin strength. I rate WST a long-term 'hold' due to exemplary dividend safety and a fortress balance sheet, but the current valuation is only slightly below fair value. Read the full article on Seeking AlphaNarrativ-Update • Apr 27
WST: Higher Margin Mix And Contract Services Expansion Will Support Earnings Power
Analysts have lifted the implied fair value estimate for West Pharmaceutical Services by about $11 to roughly $350, as a series of recent price target changes reflect updated assumptions around growth, margins and P/E multiples. Analyst Commentary Recent Street research on West Pharmaceutical Services shows a mix of upbeat and cautious messages as analysts recalibrate their models and price targets around updated assumptions for growth, margins and P/E multiples.Narrativ-Update • Feb 07
WST: Margin Resilience And Drug Delivery Portfolio Shift Will Support Earnings Power
Analysts have trimmed their price target on West Pharmaceutical Services by about US$7. This reflects updated assumptions around slightly softer revenue growth, a modestly higher discount rate, a small adjustment to future P/E expectations, and a marginally stronger profit margin outlook.Narrativ-Update • Jan 24
WST: 2026 Drug Delivery Focus And New Syringe Platform Will Support Earnings Power
Analysts have kept their fair value estimate for West Pharmaceutical Services steady at about $345.71 per share, with only slight tweaks to assumptions like the discount rate, long term revenue growth, profit margin, and future P/E, which together feed into their updated price target narrative. What's in the News West Pharmaceutical Services agreed to sell all manufacturing and supply rights for its SmartDose 3.5 mL On Body Delivery System, along with associated facilities, to AbbVie for total consideration of US$112.5 million at close, subject to working capital and other adjustments (Key Developments).Narrativ-Update • Jan 07
WST: Normalizing Markets And 2026 Visibility Will Support Earnings Power
Narrative update The updated analyst price target for West Pharmaceutical Services reflects a largely steady fair value near US$346. Analysts point to recent target hikes, higher EPS estimates and a constructive view on growth drivers into 2026 as key supports for the current valuation framework.Narrativ-Update • Dec 19
WST: Normalizing End Markets Will Support Stronger Earnings Base Into 2026
Analysts have modestly raised their price target on West Pharmaceutical Services to approximately $370, up from about $310. This reflects increased earnings estimates, a stronger setup into 2026, and improving, more stable end markets.Narrativ-Update • Dec 05
WST: Normalizing End Markets Will Support Strong Earnings Base Into 2026
Analysts have nudged their price target for West Pharmaceutical Services slightly higher to approximately $370, reflecting increased confidence in the company’s earnings power and growth drivers as market conditions normalize and set up favorably into 2026. Analyst Commentary Analyst views on West Pharmaceutical Services remain broadly constructive, with recent target hikes reflecting growing conviction that the company can sustain its earnings recovery as end markets normalize into 2026.Narrativ-Update • Nov 21
WST: Strong 2025 Outlook and Management Confidence Will Sustain Positive Momentum
West Pharmaceutical Services has seen its average analyst price target raised, with significant increases attributed to strong quarterly results, growing end market confidence, and a positive management outlook for 2026, according to analysts. Analyst Commentary Analysts have responded to West Pharmaceutical Services' recent performance and outlook with a range of observations tying directly to the company's valuation, execution, and growth prospects.Narrativ-Update • Nov 07
WST: Sustained Earnings Momentum Will Drive Confidence Into 2026
West Pharmaceutical Services has seen its average analyst price target rise from approximately $321 to $351. Analysts cite continued growth drivers and improved market conditions following a strong quarterly performance.Narrativ-Update • Oct 23
Analysts Raise Target for West Pharmaceutical Services Amid Strong Outlook and Upgraded Guidance
Analysts have increased their price target for West Pharmaceutical Services by $5 to $321. They cited the company's encouraging earnings call, management's confidence in future estimates, and stable end markets with improving investment sentiment.Analyseartikel • Jul 25
West Pharmaceutical Services, Inc.'s (NYSE:WST) Shares Climb 25% But Its Business Is Yet to Catch Up
West Pharmaceutical Services, Inc. ( NYSE:WST ) shareholders have had their patience rewarded with a 25% share price...Analyseartikel • Jul 13
Here's Why West Pharmaceutical Services (NYSE:WST) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Seeking Alpha • Mar 11
West Pharmaceutical: Remains A Strong Long-Term Prospect
Summary West Pharmaceutical Services has faced a challenging year, underperforming against the index, with declining volumes, margins, and returns, but remains a strong long-term investment. The company's high-value products segment, driven by GLP-1 medications and biologics, is expected to boost margins and returns significantly. Despite poor timing in share buybacks and management concerns, West's valuation suggests a potential 12.8% annual return, making it a buy. Key risks include management's strategic decisions and valuation, but the worst seems behind, with attractive prices for long-term growth. Read the full article on Seeking AlphaSeeking Alpha • Feb 17
West Pharmaceuticals Takes A Plunge, But May Still Offer Opportunities
Summary The price of West Pharmaceutical Services plunged over 38% after it released its Q4 and FY 2024 earnings results on February 13. Shareholders, mostly institutional investors apparently, did not like the bottom-line results nor the uninspiring guidance for 2025. Still, West should not be overlooked, and there may be opportunities if the share price continues to rebound after a market overreaction. Read the full article on Seeking AlphaSeeking Alpha • Jan 08
West Pharmaceuticals: Cannot Wrap My Head Around Valuations (Rating Downgrade)
Summary West Pharmaceutical Services stock is down 16% on deteriorating fundamentals. WST's business is contracting, with lower sales growth, compressed margins, and declining ROIC, making current valuations unjustifiable. Industry advantages exist, but high multiples and low incremental returns suggest limited compounding ability. I revise WST to hold with a $300-$330/share valuation, emphasizing the need for it to produce 4%+ sales growth and improved ROIC FY'26 to justify current prices. Read the full article on Seeking AlphaSeeking Alpha • Oct 11
West Pharma's Destocking Dilemma: Why Staying On The Sidelines Makes Sense
Summary West Pharmaceutical Services' stock has been sluggish, trading near its 52-week low, with analysts downgrading estimates and technical indicators pointing to further downside. The company has a strong market position in injectable drug delivery systems, but post-COVID demand normalization and destocking have impacted recent performance. Despite robust seasonal trends, the stock is vulnerable to tax-loss selling, with Morgan Stanley naming it among the most at-risk stocks. Given these factors, a cautious hold on West Pharma is recommended, awaiting potential recovery in Q4 and beyond. Read the full article on Seeking AlphaAnalyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$543m |
| Dec 31 2025 | US$7m | US$1m | US$494m |
| Sep 30 2025 | n/a | n/a | US$492m |
| Jun 30 2025 | n/a | n/a | US$488m |
| Mar 31 2025 | n/a | n/a | US$467m |
| Dec 31 2024 | US$8m | US$1m | US$493m |
| Sep 30 2024 | n/a | n/a | US$500m |
| Jun 30 2024 | n/a | n/a | US$525m |
| Mar 31 2024 | n/a | n/a | US$569m |
| Dec 31 2023 | US$9m | US$1m | US$593m |
| Sep 30 2023 | n/a | n/a | US$559m |
| Jun 30 2023 | n/a | n/a | US$519m |
| Mar 31 2023 | n/a | n/a | US$552m |
| Dec 31 2022 | US$8m | US$1m | US$586m |
| Sep 30 2022 | n/a | n/a | US$631m |
| Jun 30 2022 | n/a | n/a | US$686m |
| Mar 31 2022 | n/a | n/a | US$684m |
| Dec 31 2021 | US$9m | US$1m | US$662m |
| Sep 30 2021 | n/a | n/a | US$613m |
| Jun 30 2021 | n/a | n/a | US$519m |
| Mar 31 2021 | n/a | n/a | US$423m |
| Dec 31 2020 | US$8m | US$989k | US$346m |
| Sep 30 2020 | n/a | n/a | US$312m |
| Jun 30 2020 | n/a | n/a | US$286m |
| Mar 31 2020 | n/a | n/a | US$261m |
| Dec 31 2019 | US$7m | US$936k | US$242m |
Vergütung im Vergleich zum Markt: EricDie Gesamtvergütung ($USD7.19M) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD14.81M).
Entschädigung vs. Einkommen: EricDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Eric Green (56 yo)
11.2yrs
Amtszeit
US$7,190,876
Vergütung
Mr. Eric M. Green serves as Independent Director at Ecolab Inc. since December 08, 2022. He has been the Chief Executive Officer of West Pharmaceutical Services, Inc. since April 24, 2015 and its President...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Non-Independent Chair of the Board | 11.2yrs | US$7.19m | 0.25% $ 57.4m | |
| Senior VP & CFO | less than a year | US$11.80m | 0.0042% $ 953.3k | |
| Chief HR Officer & Senior VP | 10.7yrs | US$1.39m | 0.024% $ 5.4m | |
| SVP & Chief Proprietary Segment Officer | 1.1yrs | US$2.40m | 0.00087% $ 196.5k | |
| VP of Finance & Chief Accounting Officer | 6.1yrs | keine Daten | 0.0022% $ 487.9k | |
| Senior VP & CTO | less than a year | keine Daten | keine Daten | |
| Vice President of Investor Relations | no data | keine Daten | keine Daten | |
| Senior VP | less than a year | keine Daten | keine Daten | |
| Vice President of Global Communications | no data | keine Daten | keine Daten | |
| Senior Vice President of Strategy & Corporate Development | 2.6yrs | keine Daten | 0.00079% $ 178.5k | |
| Senior VP and Chief Quality & Regulatory Officer | 4.1yrs | keine Daten | keine Daten | |
| President of Contract Manufacturing | 2.2yrs | keine Daten | keine Daten |
2.4yrs
Durchschnittliche Betriebszugehörigkeit
56yo
Durchschnittliches Alter
Erfahrenes Management: WSTDas Führungsteam des Unternehmens gilt als erfahren (2.4 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Non-Independent Chair of the Board | 11.1yrs | US$7.19m | 0.25% $ 57.4m | |
| Independent Director | 12.3yrs | US$344.94k | 0.025% $ 5.6m | |
| Lead Independent Director | 6.3yrs | US$353.84k | 0.0067% $ 1.5m | |
| Independent Director | 18.7yrs | US$355.94k | 0.062% $ 14.0m | |
| Independent Director | 1.5yrs | US$330.94k | 0.0022% $ 506.0k | |
| Independent Director | 15.3yrs | US$344.94k | 0.062% $ 13.9m | |
| Independent Director | 15.3yrs | US$329.94k | 0.065% $ 14.6m | |
| Independent Director | 9.8yrs | US$332.14k | 0.016% $ 3.5m | |
| Independent Director | 3.9yrs | US$329.94k | 0.0039% $ 874.2k | |
| Independent Director | 14.3yrs | US$329.94k | 0.045% $ 10.1m | |
| Independent Director | 9yrs | US$334.94k | keine Daten | |
| Independent Director | 4.8yrs | US$343.84k | 0.0051% $ 1.2m |
10.4yrs
Durchschnittliche Betriebszugehörigkeit
66yo
Durchschnittliches Alter
Erfahrener Vorstand: WSTDie Vorstandsmitglieder sind sehr erfahren ( 10.4 ).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/09 10:33 |
| Aktienkurs zum Tagesende | 2026/06/09 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
West Pharmaceutical Services, Inc. wird von 26 Analysten beobachtet. 14 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Lawrence Marsh | Barclays |
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |